ReviewClinical and translational imaging
The role of
Review in Clinical and translational imaging. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis.Medical oncology (Northwood, London, England) · 2017Trial
- Validation of 3 high-risk resectable hepatocellular carcinoma models.Translational gastroenterology and hepatology · 2026Article
- Health-related quality of life and survival of patients with hepatocellular carcinoma treated with transarterial chemoembolization and Yttrium-90.Journal of the Egyptian National Cancer Institute · 2025Article
- Evaluation of long axial field-of-view (LAFOV) PET/CT for post-treatment dosimetry in Yttrium-90 radioembolization of liver tumors: a comparative study with conventional SPECT imaging.European journal of nuclear medicine and molecular imaging · 2025Article
- Article
- Is the Y90-radioembolization treatment effective on the intermediate-advanced stage of hepatocellular carcinoma and what is the albumin-bilirubin score's prediction factor for survival?Hepatology forum · 2023Article
- Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Article
- Narrative review of the role of yttrium-90 selective internal radiation therapy in the surgical management of colorectal liver metastases.Journal of gastrointestinal oncology · 2021Review
- Liver-Directed Therapies for Neuroendocrine Neoplasms.Current oncology reports · 2021Review
- Metastatic Papillary Thyroid Cancer to the Liver: The Central Role of a Multidisciplinary Approach to Treatment.Ochsner journal · 2021Article
- Feasibility of Combination Intra-arterial Yttrium-90 and Irinotecan Microspheres in the VX2 Rabbit Model.Cardiovascular and interventional radiology · 2020Article
- Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm.Journal of gastrointestinal oncology · 2020Review
- Contralateral Liver Hypertrophy and Oncological Outcome Following Radioembolization withCancers · 2020Review
- Transarterial radioembolization for liver tumors as neoadjuvant therapy: three case reports.Einstein (Sao Paulo, Brazil) · 2020Article
- Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models.Seminars in radiation oncology · 2020Review
- Primary hepatic melanoma: A case report of computed tomography and magnetic resonance imaging findings.Medicine · 2019Article
- Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors.Journal of cancer research and clinical oncology · 2017Article
- Prognostic Impact of Cirrhosis in Patients with Intrahepatic Cholangiocarcinoma following Hepatic Resection.Canadian journal of gastroenterology & hepatology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radioembolization (RE) is an emerging treatment strategy for patients with primary hepatic malignancies and metastatic liver disease. Though RE is primarily performed in the palliative setting, a shift toward the curative setting is seen. Currently, hepatic resection and in selected cases liver transplantation are the only curative options for patients with a hepatic malignancy. Unfortunately, at diagnosis most patients are not eligible for liver surgery due to the imbalance between the necessary liver resection and the remaining liver remnant. However, in borderline resectable cases, tumor volume reduction and/or increasing the future liver remnant can lead to a resectable situation. The combination of selective tumor treatment, the induction of hypertrophy of untreated liver segments, and its favourable toxicity profile make RE an appealing strategy for downstaging. The present review discusses the possibilities for RE in the preoperative setting as a downstaging tool or as a bridge to liver transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.